Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of Brentuximab Vedotin Administered Sequentially and Concurrently With Multi-Agent Chemotherapy as Front-Line Therapy in Patients With CD30-Positive Mature T-Cell and NK-Cell Neoplasms, Including Systemic Anaplastic Large Cell Lymphoma

Next Previous
Trial Profile

A Phase 1 Study of Brentuximab Vedotin Administered Sequentially and Concurrently With Multi-Agent Chemotherapy as Front-Line Therapy in Patients With CD30-Positive Mature T-Cell and NK-Cell Neoplasms, Including Systemic Anaplastic Large Cell Lymphoma

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 27 Oct 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
  • Indications Anaplastic large cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; T-cell leukaemia; T-cell lymphoma
  • Focus Adverse reactions
  • Sponsors Seagen; Seattle Genetics

    • Most Recent Events

    • 05 Mar 2018 Results assessing durability of response and overall survival after 5 years published in the Blood
    • 12 Dec 2017 Five-year survival results (n=26) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 10 Dec 2017 Results published in the Seattle Genetics (n=26) Media Release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top